Results · Apr-Jun 2026
Rossari Biotech Q1 FY27 results
Sales grew 28% to ₹697 crore from ₹544 crore in Apr-Jun 2025.
Operating profit grew 19% to ₹80.6 crore, an operating margin of 11.6% (down 0.9 points from a year ago).
Net profit grew 4% to ₹35.1 crore from ₹33.6 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +2%, net profit −24%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 697.2 | 543.7 | +28% |
| Operating profit (EBITDA) | 80.6 | 67.9 | +19% |
| Operating margin | 11.6% | 12.5% | −0.9 pts |
| Net profit | 35.1 | 33.6 | +4% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.